Skip to content

To evaluate the effect of herbal medicine in prevention and management of COVID-19

To evaluate the impact of Unani polyherbal formulation in the prophylaxis and clinical management of COVID-19

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/06/025672
Enrollment
60
Registered
2020-06-06
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

Interventions

Intervention1: Joshanda (Decoction): Joshanda (Decoction) of the following: 1. Anjeer (Ficus carica L.) 3 Nos. 2. Unnab (Ziziphus jujuba Mill.) 5 Nos. 3. Sapistan (Cordia dichotoma Forst. f) 7 Nos. 4

Sponsors

Ministry of AYUSH Government of India
Lead Sponsor
National Institute of Unani Medicine
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: 1. Definite diagnosis of COVID-19; fulfilling WHO case definition, including a positive PCR from any specimen (e.g. respiratory, blood, urine, stool, other bodily fluid) and presence of one or more of the following associated symptoms- cough fever ( > 37.5° C / 99.5° F) shortness of breath sore throat 2. Hospitalized patients with no oxygen therapy or oxygen by mask or nasal prongs. 3. Understand and agreed to comply with the study

Exclusion criteria

Exclusion criteria: 1. Patient below 18 year of age. 2. K/c/o Cardiovascular diseases like Ischaemic heart disease, Coronary Artery disease. 3. K/c/o Chronic Kidney disease, Chronic Lung disease, Chronic neurological disorder, Pulmonary Tuberculosis. 4. Pregnant and Lactating women. 5. Patient on non-invasive ventilation or high flow oxygen. 6. Patient on intubation and mechanical ventilation. 7. Patient on ventilation + additional organ support-pressor, RRT, ECMO.

Design outcomes

Secondary

MeasureTime frame
NILTimepoint: NIL

Primary

MeasureTime frame
The outcome will be focused on decrease severity of parameters: â?? Fever â?? Sore Throat, Cough with sputum, Cough with haemoptysis, Dyspnoea (Shortness of breath), Wheezing, Chest pain, Runny nose, Fatigue, Headache, Arthralgia, Irritability/confusion, Seizures, Nausea/Vomiting, Diarrhoea, Abdominal pain, skin rashesTimepoint: 0th Day, 14th Day and 21st Day

Countries

India

Contacts

Public ContactDr Fasihur Rehman Ansari

National Institute of Unani Medicine

dr.mariyamahad@gmail.com9412456250

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026